Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects the joints. The conventional system of medicine offers a wide range of treatments, but there is no cure for RA. In the Unani system of medicine, several Unani formulations and regimens are effectively used to manage Waja‘al-Mafāṣil (RA). Therefore, the present case report aimed to evaluate the efficacy and safety of the Unani formulation (Nuskha-e-Munzij) along with wet cupping (Ḥijāma bi’l Sharṭ) as an adjuvant therapy for RA. A 40-year-old female patient diagnosed with RA, based on the 2010 ACR/EULAR Rheumatoid Arthritis classification criteria, was treated with standard treatment along with Unani formulation (Nuskha-e-Munzij), in the form of a decoction, which was given for 21 days, after which wet cupping (Ḥijāma bi’l Sharṭ) was performed, 3 sittings fortnightly. The patient showed a significant reduction in subjective parameters (i.e., VAS, DAS 28 score, swelling, stiffness, restricted movement, tenderness) and objective parameters (i.e., CRP, RA factor, and ESR). RA factor (quantitative) was 260 IU/ml at baseline, significantly reduced to 88.9 IU/ml after 7 weeks of treatment. There were no adverse effects reported during the treatment. Therefore, Unani formulation (Nuskha-e-Munzij) and wet cupping (Ḥijāma bi’l Sharṭ) were found effective and safe for treating rheumatoid arthritis as an adjuvant therapy to standard treatment.